Summary of findings: Octreotide vs placebo
Diarrhoea (grade 2+) · People undergoing RT for pelvic cancer
Summary of findings: Octreotide showed no clear difference in diarrhoea (grade 2+) compared with placebo (moderate certainty).
1 finding from 1 review
- Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes onlyRR 1.01 [0.76, 1.35]2 studies · 340 participantsModerate